The promising preliminary results of AUGMENT-101 prompted the opening of AUGMENT-102 (NCT05326516), a phase 1 trial investigating revumenib in combination with chemotherapy in patients with KMT2A-r or NPM1-m acute leukemias. Here, NPM1 is linked to acute leukemia.